Home » Artificial Intelligence, Automation, Funding, health tech, Investments, SigTuple Bangalore-based health startup SigTuple has raised $19 million in a Series B funding led by existing investors Accel Partners and IDG Venture, with participation from Endiya Partners, pi Ventures, VH Capital, Axilor Ventures and Flipkart co-founder Binny Bansal. The startup has also raised venture debt of an undisclosed amount from Trifecta Capital. SigTuple will use the money to expand assembly and distribution of AI100 — a smart device that enables digitisation of different biological samples like blood, urine and semen. “The major chunk (of the money) will go into setting up a manufacturing pipeline so that we can put more devices in the market,” said Rohit Kumar Pandey, chief executive at SigTuple . “We have applied for US FDA and CE certification. Once we go through the stage, it will require more clinical trials for different market deployments.” The startup in a Series A funding in 2017. The startup is building products for automated analysis of medical scans and data to provide a diagnosis. Its primary product is Manthana, an AI platform which provides solutions for analysis of peripheral blood smears, urine and semen sample, retinal scans and chest x-rays. The peripheral blood smear tool Shonit has undergone trials and is being used in beta by partners. I cover health, policy issues such as intermediary liability, data governance, internet shutdowns, and more. Hit me up for tips.
Health start-up SigTuple has raised $19m in series B funding led by existing investors Accel Partners and IDG Ventures, along with an undisclosed amount of venture debt from Trifecta Capital. The Indian-based AI company will use the funding to expand production of its AI100 smart device, which digitises biological samples such as blood, urine and semen. “SigTuples’ technology is a game-changer for healthcare professionals who want to analyze large amounts of data quickly and efficiently,” said CEO Amit Agarwal.